What No One Wants to Confront About the Neera Tanden Nomination Noise

by | Feb 25, 2021 | Politics & Corruption

What No One Wants to Confront About the Neera Tanden Nomination Noise

by | Feb 25, 2021 | Politics & Corruption

More ink and pixels are being expended every day over the nomination of Neera Tanden to run the Office of Management and Budget.
More ink and pixels are being expended every day over the nomination of Neera Tanden to run the Office of Management and Budget. Neera Tanden it turns out has what some think is a bad habit of being outspoken. Most of the people doing the objecting are Republican Senators, with one exception.

First, Republicans objecting to someone calling people out with “mean tweets” would frankly be hilarious except for the 4-year barrage of mean tweets these same people had apparently no problems with.

Now let’s take a look at the lone Democratic Senator objecting to Neera Tanden. What’s the deal here. Senator Joe Manchin (D) of West Virginia is objecting to this nomination but for much more disingenuous reasons.

Newsweek has a story that Neera Tanden criticized Heather Bresch of Mylan Pharma for her massive salary increase a few years back. Mylan ran the price of EpiPens up to $600 per unit and engaged in all manner of anti-competitive behaviors. Well, Heather Bresch’s father is Joe Manchin.

Thanks to Newsweek for exposing this factor. The Republican factor we can understand (sort of). Raising objections to critical tweets is something these folks have wanted to do for over four years but were just too frightened of their own shadows, and of course the ill will of Trump.

But Manchin’s actions now look much more like petty revenge for a slight against his daughter.

If an unpleasant odor rises from this whole affair, it should. As with almost every other pharma company, the word cartel is better used when describing Mylan’s business practices with regards to their pricing and actions taken against competition.


Submit a Comment

Your email address will not be published.

Related Articles

Oct 05 2022

Voting Rights Are First Up on the Docket at the Supreme Court

Black voters make up more than a quarter of the Alabama’s population, but only one congressional district would be majority Black under the voting map drawn by...
Oct 04 2022

Big Pharma-Funded FDA Gets Drugs Out Faster, but at What Cost?

In 1992 Congress passed a law committing the drug industry to pay so-called user fees to help fund the FDA’s drug approval process. Big Pharma has used that law to...
Sep 26 2022

The Koch Network Is Financing Election Deniers With Campaign Cash Ahead of Midterms

Charles Koch and his billionaire buddies in the Koch Network continue their pattern of trying to tear down our government by funding candidates who tried to turn our...
Sep 25 2022

How the Supreme Court Unleashed a Corporate Criminal Takeover of America

Because of key decisions by the Supreme Court equating money with free speech, our political system is now overrun with grifters, con artists and career...
Sep 22 2022

New York’s Lawsuit Against Donald Trump — A Tax Lawyer Explains What’s at Stake

While the New York Attorney General’s massive lawsuit against Donald Trump, his children and companies is a civil suit, it marks a beginning and an acceleration...
Sep 21 2022

How Privatization and Corruption Magnified Puerto Rico’s Vulnerability to Hurricanes

Still recovering from the 2017 disaster of Hurricane Maria, which killed 3000 Americans in Puerto Rico, the islands have been blacked again out by much smaller...
Sep 17 2022

What Is Behind the Diminishing Trust in Government Institutions?

Our government institutions are the glue that actually holds our society together and keep things rolling. What happens when that glue stops sticking?
Sep 15 2022

The Sacklers and Purdue Pharma Were Not Alone in Creating and Profiting From the Opioid Crisis

The Sacklers became the public face of the opioid crisis despite not being the only players. They were the first to hypermarket opioids and then led the pack in blaming...
U.S. Rep. Josh Gottheimer (D-N.J.) speaks during an April 6, 2022 press conference at the U.S. Capitol. Gottheimer is among the nearly 100 members of U.S. Congress whose ownership or trading of financial assets overlapped with their committee work. (Photo: Kevin Dietsch/Getty Images)
Sep 14 2022

Conflict of Interest: Members of Congress Trading Stocks

We need more action on legislation that would ban Congressional stock trading. And fewer members of Congress in violation of the rules already on the books.
Sep 13 2022

The Tax Money Sinkhole That Is the American Weapons Industry

Military contractors and arms manufacturers and other weapons industry players cash in as Congress adds billions to the Pentagon budget each year.
Subscribe for Updates!

Subscribe for Updates!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Pin It on Pinterest

Share This